Coincidental alterations of p16(INK4A/CDKN2) and other genes in human lung cancer cell lines

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1537-1542

  Fujishita, T ^a   Mizushima, Y ^a   Kashii, T ^a   Kobayashi, M ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

CDK inhibitor genes; K ras p53; Lung cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; CARRIER PROTEIN; CDKN1A PROTEIN, HUMAN; CDKN2B PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; PRIMER DNA; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG CARCINOGENESIS; ONCOGENE C MYB; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE; CELL CULTURE; CELL LINE; CHEMISTRY; COLON TUMOR; DRUG ANTAGONISM; EXON; FRAMESHIFT MUTATION; GENE DELETION; GENETICS; ISOLATION AND PURIFICATION; LUNG TUMOR; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; ONCOGENE RAS; PANCREAS TUMOR; PATHOLOGY; POINT MUTATION;

BASE SEQUENCE; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL LINE; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA PRIMERS; DNA, NEOPLASM; EXONS; FRAMESHIFT MUTATION; GENES, MYC; GENES, RAS; GENES, RETINOBLASTOMA; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; PANCREATIC NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE DELETION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0031594951     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kashii T, Mizushima Y, Nakagawa K et al: Amplification of the N-myc oncogene in an adenocarcinoma cell line of the lung. Anticancer Res 12: 621-624, 1992.
2. Kashii T, Mizushima Y, Monno S et al: Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method. J Cancer Res Clin Oncol 120: 143-148, 1994.
3. Kashii T, Mirushima Y, Lima CEQ et al: Studies on clinicopathological features of lung cancer patients with K-ras/p53 gene alterations: comparison between younger and older groups. Oncology 52: 219-225, 1995.
4. Fujishita T, Mizushima Y, Kashii T et al: No occurrence of DNA polymerase β gene mutation in human lung carcinoma cell lines with K-ras, p53, or Rb gene alterations. Oncol Rep 2: 755-757, 1995.
5. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.
6. Kamb A, Gruis NA, Weaver-Feldhaus J et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
7. Nobori T, Miura K, Wu DJ et al: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
8. Caldas C, Hahn SA, da Costa LT et al: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8: 27-32, 1994.
9. Jen J, Harper JW, Bigner SH et al: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994.
10. Mori T, Miura K, Aoki T et al. Frequent somatic mutation of the MTS1/CDK4I/(multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54: 3396-3397, 1994.
11. INK4α gene product in human pituitary tumors. Cancer Res 56: 2493-2496, 1996.
12. Heinzel PA, Balaram P and Bernard HU: Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer 68: 420-423, 1996.
13. Zhang S, Endo S, Koga H et al: A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations. Jpn J Cancer Res 87: 900-907, 1996.
14. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 11672: 156-159, 1987.
15. Orita M, Suzuki Y, Sekiya T et al: Rapid and sensitive detection of point mutations and DNA polymorphisms using polymerase chain reaction. Genomics 5: 874-879, 1989.
16. Sanger F, Nicklen S and Coulson AR: DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5467,1977.
17. Lazaro C and Estivill X: Mutation analysis of genetic diseases by asymmetric-PCR SSCP and ethidium bromide staining: application to neurofibromatosis and cystic fibrosis. Moll Cell Probes 6: 357-359, 1992.
18. Hayashi N, Sugimoto Y, Tsuchiya E et al: Somatic mutations of the MTS(multiple tumor suppressor )1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202: 1426-1430, 1994.
19. de Vos S, Miller CW, Takeuchi S et al: Alterations of CDKN2(p16) in non-small cell lung cancer. Genes Chromosome Cancer 14: 164-170, 1995.
20. Nakagawa K, Conrad NK, Williams JP et al: Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene 11: 1843-1851, 1995
21. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55: 1448-1451, 1995.
22. Washimi O, Nagatake M, Osada H et al: In vivo occurrence of p16(MTS1) and p15(MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 55: 514-517, 1995.
23. INK4B and p18 genes in primary non-small-cell lung cancers. Int J Cancer 65: 734-739, 1996.
24. INK4a tumor suppressor protein. Cancer Res 55; 2503-2506, 1995.
25. Merlo A, Herman JG, Mao L et al: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1: 686-692, 1995.
26. Herman JG, Merlo A, Mao L et al: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
27. Naumann M, Savitskaia N, Eilert C et al: Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110: 1215-1224, 1996.
28. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378, 1994.
29. INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509, 1995.
30. Chedid M, Michieli P, Lengel C et al: A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9: 3021-3024, 1994.
31. Shiohara M, El-Deiry WS, Wada M et al: Absence of WAF1 mutations in a variety of human malignancies. Blood 84: 3781-3784, 1994.
32. Kawamata N, Morosetti R, Miller CW et al: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55: 2266-2269, 1995.